SCHEMBL4867343

SCHEMBL4867343

O=C(NCc1ccc(F)c(Cl)c1)N1CCCOc2cc(F)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
MAPK1 P28482 1/20 0.41
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KCNQ2 O43526 1/20 0.41
PKM P14618 1/20 0.40
DGAT1 O75907 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
EGFR P00533 3/20 0.40
CNR2 P34972 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
AVPR2 P30518 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
DUSP3 P51452 1/20 0.39
PTPN5 P54829 1/20 0.39
CASP6 P55212 1/20 0.39
PTPN11 Q06124 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867216 0.92 MAPT (0.43) MAPTLMNAMEN1KMT2AKCNQ2
SCHEMBL4866045 0.89 KMT2A (0.50) MAPTLMNAMEN1KMT2AKCNQ2
SCHEMBL4867190 0.87 P2RX7 (0.45) MAPTMEN1KMT2AKCNQ2DGAT1
SCHEMBL4871337 0.86 P2RX7 (0.47) MEN1KMT2APKMTSHR
SCHEMBL4870612 0.84 KCNQ2 (0.43) MAPTMEN1KMT2AKCNQ2DGAT1
SCHEMBL4870624 0.78 DGAT1 (0.46) MAPTKCNQ2DGAT1TP53POLB
SCHEMBL4867013 0.78 TSHR (0.64) MAPTLMNAMEN1KMT2APKM
SCHEMBL4869580 0.78 MAPT (0.42) MAPTLMNAPKMDGAT1TSHR
SCHEMBL25937553 0.75 KCNQ2 (0.45) MAPTKCNQ2DGAT1HPGDTSHR
SCHEMBL25333702 0.73 KCNQ2 (0.47) MAPTLMNAKCNQ2PKMDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885MAPK1 2006/4885LMNA 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.